Key Drivers
- Strong cash position
- Zero reported revenue
- High cash burn
AIAI Summary
Annexon's valuation has shifted from R&D-stage to a binary, near-term regulatory/commercial inflection—tanruprubart's EMA MAA and planned BLA mean approval outcomes (and FORWARD/FDA interactions) will either unlock significant first‑in‑class upside or force dilutive financing within 12–24 months, so investors should closely monitor BLA acceptance, FORWARD data signals, and any partnership/milestone financing as immediate catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash position
- •Zero reported revenue
- •High cash burn
ANNX has ample cash and low leverage but no revenue and persistent operating/free-cash-flow losses that have shrunk equity and produce negative returns while the company relies on financing and heavy R&D spend.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Support holding
- •Lower highs
Price at $5.11 sits below the last month SMA (~$5.43) with RSI ~45, signaling a mild short-term downtrend where $4.89–$4.90 is key support to hold or its breach confirms weakness while reclaiming $5.43 (and $6.08/$6.50–$6.96) would be needed to restore bullish momentum.
Recent peak near $6.08 on 2026-03-10 followed by a sequence of lower highs indicating fading upside
Sentiment & News
Key News Insights:
- •Consensus target
- •Mixed coverage
- •IR & hiring
Annexon received a $17 consensus price target and a "Moderate Buy" average from seven analysts (5 buys/1 hold/1 sell) while boosting investor outreach via a TD Cowen presentation and an inducement equity grant, with no clinical or regulatory catalysts reported.
Modestly positive for sentiment and visibility, but limited near-term upside without clinical or regulatory catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings